Updated results from the CheckMate 274 trial support the use of adjuvant nivolumab as standard care for high-risk muscle-invasive urothelial carcinoma, according to researchers.

Tyra Biosciences' shares have dropped sharply after interim data from TYRA-300 showed a superior but not exceptional adverse ...

First-of-its-kind research looking at survival rates for patients with incurable larynx cancer has been published.

Craig A Clifford, DVM, MS, DACVIM (Oncology) talks about the most common bladder tumor in dogs, misdiagnosis, and the Cadet ...

Dogs trained to detect bladder cancer showed 90% sensitivity and 95% specificity, offering a non-invasive diagnostic method.

Discover how voided urine cfDNA emerges as a promising biomarker for upper tract urothelial carcinoma, offering a less ...

A study led by the University of Bristol and published in Veterinary and Comparative Oncology has demonstrated that trained ...

AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), pote ...

Urothelial carcinoma (UC), also known as transitional cell carcinoma (TCC), is the most common form of bladder cancer in dogs ...

US FDA grants priority review status to AstraZeneca’s sBLA for Imfinzi to treat patients with muscle-invasive bladder cancer: Cambridge, UK Saturday, December 7, 2024, 09:00 Hrs ...

For a definitive diagnosis, histopathology of a biopsy sample is needed ... Paper 'Trained dogs can detect canine urothelial ...

Bladder tumors, though less discussed than other forms of cancer, are a significant health concern. They arise from the lining of the urinary tract, known as th ...